Method for inhibiting the conversion of deoxynivalenol-3-glucoside into deoxynivalenol

Abstract

The present invention provides a method for inhibiting the conversion of deoxynivalenol-3-glucoside (D3G) into deoxynivalenol (DON). The method comprises treating D3G or a system containing it with a sugar. The present invention optimizes the types of sugars and finds that cellobiose has an unexpected conversion inhibition effect.

Description

Technical Field

[0001] The present invention belongs to the field of mycotoxin prevention and control; more specifically, the present invention relates to a method for inhibiting the conversion of deoxynivalenol-3-glucoside (D3G) into deoxynivalenol (DON). Background Art

[0002] Deoxynivalenol-3-glucoside (D3G) is the glycosylated form of deoxynivalenol (DON) and is a modified fungal toxin. DON, the prototype toxin of D3G, is a Fusarium toxin with immunotoxicity, organ toxicity, protein synthesis inhibition and teratogenicity. Under improper storage conditions, grains are easily contaminated by fungi and produce DON. When DON is ingested by humans or animals, it can cause serious health problems. D3G usually appears together with its prototype toxin DON. In some grains and grain products, the sample incidence of D3G is even higher than that of DON.

[0003] According to a regional statistical result in 2016, the most common mycotoxins in wheat flour samples (n=359) were DON (97.2%), nivalenol (40.4%) and D3G (33.4%), with average contamination levels of positive samples of 86.7, 3.55 and 3.34 μg / kg, respectively. In a 2021 research report, almost all contaminated natural feed corn samples (100%) in northern Germany contained D3G, with a content as high as 3038 μg / kg.

[0004] As D3G has received increasing international attention, researchers have also developed and optimized various detection methods for DON and its hidden toxin D3G. The most commonly used chromatographic methods for determining type B trichothecenes include gas chromatography (GC), gas chromatography and mass spectrometry (GC / MS), high performance liquid chromatography (HPLC), and LC-MS / MS. Currently, LC-MS / MS is considered to be the most widely used analytical technique for determining a variety of mycotoxins.

[0005] For humans, grains and grain products are the main sources. On farms and ranches, the consumption of grains, grain by-products and feed corn also accounts for a large proportion. Although existing studies have shown that D3G has low toxicity to plants and mammals, D3G still has the risk of releasing its prototype toxin DON in some cases. It is reported that D3G can be converted into DON during some food processing processes such as dough extrusion, fermentation and steaming. Studies have shown that certain intestinal microorganisms in animals have the ability to quickly hydrolyze D3G and release DON both in vivo and in vitro. What is more noteworthy is that researchers have found that certain microbial communities in human feces can also convert D3G into DON very efficiently, which undoubtedly increases the toxic burden of exposed individuals.

[0006] In the Lactobacillaceae family, Lactobacillus plantarum is found in different ecological niches and is used in many food fermentations and commercial probiotic products, so it is often present in the human diet. At the same time, this bacterium is also part of the human colonic microbiota and the gastrointestinal tract of animals. Some Lactobacillus plantarum strains have been reported to have tannase activity, which is able to hydrolyze harmful anti-nutritional compounds - tannins into glucose and gallic acid. Therefore, some Lactobacillus plantarum strains are able to respond to these toxic compounds and use them as energy sources, thereby selectively stimulating their growth. As early as 2011, it was reported that the model strain of Lactobacillus plantarum was able to convert D3G into its prototype toxin DON.

[0007] Therefore, there is an urgent need in the art to develop methods for inhibiting the conversion of D3G into its prototype toxin DON. Summary of the invention

[0008] The object of the present invention is to provide a method for inhibiting the conversion of deoxynivalenol-3-glucoside (D3G) into deoxynivalenol (DON), and application thereof.

[0009] In a first aspect of the present invention, a method for inhibiting the conversion of deoxynivalenol-3-glucoside (D3G) into deoxynivalenol (DON) is provided, comprising: treating deoxynivalenol-3-glucoside or a system containing the same with sugars to inhibit the conversion of deoxynivalenol-3-glucoside into deoxynivalenol.

[0010] In one or more embodiments, the carbohydrate comprises monosaccharide or disaccharide, or a combination thereof.

[0011] In one or more embodiments, the sugar is selected from: cellobiose, glucose, sucrose, maltose, trehalose, or a combination thereof.

[0012] In one or more embodiments, the carbohydrate is cellobiose.

[0013] In one or more embodiments, inhibiting the conversion of deoxynivalenol-3-glucoside to deoxynivalenol includes: inhibiting the conversion of deoxynivalenol-3-glucoside remaining in microorganisms producing deoxynivalenol-3-glucoside, industrial processed products or natural products into deoxynivalenol.

[0014] In one or more embodiments, the microorganism producing deoxynivalenol-3-glucoside is a microorganism capable of converting deoxynivalenol-3-glucoside into deoxynivalenol.

[0015] In one or more embodiments, the microorganism producing deoxynivalenol-3-glucoside includes (but is not limited to) bacteria or fungi.

[0016] In one or more embodiments, the microorganism is a bacterium.

[0017] In one or more embodiments, the bacteria include (but are not limited to): Lactobacillus family such as Lactobacillus plantarum, Lactobacillus amyloliquefaciens, Lactobacillus crispatus, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus paracasei, Lactobacillus rhamnosus, Enterococcus family such as Enterococcus casei, Enterococcus perseverant, Enterococcus faecium, Actinomycetaceae family such as Bifidobacterium adolescentis, Bifidobacterium family such as Bifidobacterium, Bifidobacterium longum, Enterobacteriaceae family such as Citrobacter freundii, Enterobacter cloacae.

[0018] In one or more embodiments, the microorganism includes living or inactivated microorganisms or processed products thereof.

[0019] In one or more embodiments, the microorganism is an intestinal microorganism.

[0020] In one or more embodiments, the industrial processed products include (but are not limited to): food (such as grains, grain products) or feed; preferably, the food or feed includes: fermented food or fermented feed.

[0021] In one or more embodiments, when deoxynivalenol-3-glucoside or a system containing it is treated with sugar, the final concentration of the sugar is 0.0001-100 g / L; preferably 0.0005-50 g / L; more preferably 0.001-20 g / L; more preferably 0.01-10 g / L.

[0022] In one or more embodiments, the sugar treatment is exogenous addition of sugars.

[0023] In one or more embodiments, the system containing deoxynivalenol-3-glucoside is a microbial cell system.

[0024] In one or more embodiments, when deoxynivalenol-3-glucoside or a system containing it is treated with a sugar, the final concentration of the sugar is, for example, 0.002, 0.003, 0.005, 0.008, 0.01, 0.02, 0.03, 0.05, 0.06, 0.08, 0.1, 0.2, 0.3, 0.5, 0.6, 0.8, 1, 2, 3, 5, 6, 8 or 9 g / L.

[0025] In one or more embodiments, the carbohydrate is cellobiose, and its final concentration is 0.0001-100 g / L; preferably 0.001-50 g / L; more preferably 0.01-30 g / L; optimally 0.5-20 g / L; such as 1 g / L, 10 g / L. When the cellobiose is in the preferred or optimal concentration range, its technical effect is extremely excellent.

[0026] In one or more embodiments, the sugar is glucose, and its final concentration is 0.0001-100 g / L; preferably 0.001-50 g / L; more preferably 0.1-20 g / L; such as 0.5 g / L, 1 g / L or 10 g / L.

[0027] In one or more embodiments, the sugar is fructose, and its final concentration is 0.005-100 g / L; preferably 0.01-10 g / L; more preferably 0.1-20 g / L; such as 0.5 g / L, 1 g / L or 10 g / L.

[0028] In one or more embodiments, the sugar is sucrose, and its final concentration is 0.005-100 g / L; preferably 0.01-10 g / L; more preferably 0.1-20 g / L; such as 0.5 g / L, 1 g / L or 10 g / L.

[0029] In one or more embodiments, the sugar is maltose, and its final concentration is 0.8 to 100 g / L; preferably 1 to 50 g / L; such as 2 g / L, 5 g / L or 10 g / L.

[0030] In one or more embodiments, the carbohydrate is trehalose, and its final concentration is 0.8 to 100 g / L; preferably 1 to 50 g / L; such as 2 g / L, 5 g / L or 10 g / L.

[0031] In one or more embodiments, the inhibition (inhibition of conversion) is a statistically significant inhibition or a significant inhibition, such as inhibition (reduction of toxicity) by 5%, 10%, 15%, 20%, 30%, 50%, 60%, 80%, 90%, 95% or 100%.

[0032] In another aspect of the present invention, there is provided the use of sugars for: inhibiting the conversion of deoxynivalenol-3-glucoside into deoxynivalenol; or, preparing a composition for inhibiting the conversion of deoxynivalenol-3-glucoside into deoxynivalenol; the sugars include monosaccharides or disaccharides.

[0033] In one or more embodiments, the sugar comprises a sugar selected from the group consisting of cellobiose, glucose, sucrose, maltose or trehalose.

[0034] In one or more embodiments, the carbohydrate is cellobiose.

[0035] In one or more embodiments, inhibiting the conversion of deoxynivalenol-3-glucoside to deoxynivalenol includes: inhibiting the conversion of deoxynivalenol-3-glucoside remaining in microorganisms producing deoxynivalenol-3-glucoside, industrial processed products or natural products into deoxynivalenol.

[0036] In another aspect of the present invention, a method for treating a microorganism to reduce its toxicity is provided, wherein the microorganism is a microorganism that produces deoxynivalenol-3-glucoside, or a microorganism that can convert deoxynivalenol-3-glucoside into deoxynivalenol, and the method comprises: (a) culturing the microorganism and isolating and obtaining microbial cells that can convert deoxynivalenol-3-glucoside into deoxynivalenol; and (b) treating the microbial cells of (a) with sugars, thereby reducing the activity of the microorganism in converting deoxynivalenol-3-glucoside into deoxynivalenol and reducing the toxicity.

[0037] In one or more embodiments, the reduction (reduction in toxicity) is a statistically significant inhibition or a significant inhibition, such as inhibition (reduction in toxicity) of 5%, 10%, 15%, 20%, 30%, 50%, 60%, 80%, 90%, 95% or 100%.

[0038] In one or more embodiments, the microorganism includes (but is not limited to) bacteria or fungi; preferably, the microorganism is a bacteria; more preferably, the bacteria include (but is not limited to): Lactobacillus family such as Lactobacillus plantarum, Lactobacillus amyloliquefaciens, Lactobacillus crispatus, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus paracasei, Lactobacillus rhamnosus, Enterococcus family such as Enterococcus casei, Enterococcus tenacious, Enterococcus faecium, Actinomycetaceae family such as Bifidobacterium adolescentis, Bifidobacterium family such as Bifidobacterium, Bifidobacterium longum, Enterobacteriaceae family such as Citrobacter freundii, Enterobacter cloacae.

[0039] In one or more embodiments, the microorganism includes living or inactivated microorganisms or processed products thereof.

[0040] In one or more embodiments, when the microorganism converts deoxynivalenol-3-glucoside into deoxynivalenol, D3G is used as a carbon source; preferably, D3G is used as the sole carbon source.

[0041] Other aspects of the present invention will be apparent to those skilled in the art in view of the disclosure herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 , Lactobacillus plantarum (a model lactobacillus) on D3G conversion and product toxicity evaluation. (A) D3G conversion by Lactobacillus plantarum. STD is a standard product.

[0043] Figure 2 , the inhibitory effect of different exogenously added sugars at different concentrations on the conversion of D3G to DON by Lactobacillus plantarum. DETAILED DESCRIPTION

[0044] Based on the technical difficulty that there is a lack of a method in the art to effectively prevent the conversion of deoxynivalenol-3-glucoside (D3G) into deoxynivalenol (DON), the present invention provides a solution. Based on in-depth research, the inventors have revealed a method for inhibiting the conversion of D3G into DON, which comprises treating (exogenously adding) D3G or a system containing it (such as a microbial system, an industrial processed product or a natural product) with sugars. The present invention optimizes the types of sugars and finds that cellobiose has an unexpected conversion inhibition effect.

[0045] the term

[0046] As used herein, unless otherwise specified, the term "conversion" refers to the conversion of D3G to DON, which results in an increase in toxicity. The term "inhibition of conversion" refers to a decrease in the conversion of D3G to DON, which results in a decrease in toxicity.

[0047] As used herein, the "system containing D3G" is any system in which D3G exists, is produced / synthesized, including but not limited to microorganisms, industrial processed products or natural products, etc. The system can be a living cell, a cell culture, or a processed product or natural product in a non-living form.

[0048] As used herein, the "microorganism" refers to various microorganisms that can metabolize and produce D3G or can process D3G and convert it into DON.

[0049] As used herein, the "sugar" or "sugar substance" includes monosaccharide, disaccharide or polysaccharide, preferably monosaccharide or disaccharide.

[0050] As used herein, the terms “containing”, “having” or “including” include “comprising”, “mainly consisting of…”, “substantially consisting of…”, and “consisting of…”; “mainly consisting of…”, “substantially consisting of…” and “consisting of…” are subordinate concepts of “containing”, “having” or “including”.

[0051] As used herein, "biologically acceptable carrier" refers to a solvent, suspending agent or excipient, etc., which is used to deliver the saccharide of the present invention to an object to be treated (including food and feed), and is environmentally friendly or harmless to humans and animals, with controllable toxicity and side effects. The carrier may be liquid or solid, and preferably is a carrier that can maintain the biological activity of the saccharide of the present invention to a high degree.

[0052] As used herein, the D3G is a modified toxin D3G with low toxicity, and the DON is a prototype toxin DON with high toxicity.

[0053] Methods and Applications

[0054] The invention discloses a method for inhibiting the conversion of a modified toxin D3G of DON into its prototype toxin DON, comprising treating D3G or a system containing the D3G with sugars, thereby inhibiting the conversion of D3G into DON.

[0055] In a specific embodiment of the present invention, the inventors used plant lactobacillus (a model lactobacillus) with the ability to transform D3G as an experimental subject, and finally found that exogenously added safe carbohydrate cellobiose can effectively inhibit the transformation of this plant lactobacillus to D3G by screening a variety of sugars. This method is safe, efficient and convenient, and has good application prospects. It should be understood that the model lactobacillus is used as a transformation model in the embodiment of the present invention, but the overall scheme of the present invention is not limited to the model strain.

[0056] As a preferred embodiment of the present invention, a method for inhibiting the conversion of D3G to DON by microorganisms such as Lactobacillus plantarum is provided, wherein exogenously added cellobiose is used to achieve the purpose of inhibiting the production of DON. Specifically, the following implementation method is used:

[0057] (1) A single colony of Lactobacillus plantarum from an MRS agar plate was inoculated into MRS broth and grown under dynamic incubation at 37°C for 24 hours to activate the strain;

[0058] (2) Transfer the activated bacterial solution in 1 to 25 mL of MRS broth at a ratio of 1:50 and culture for 16 h;

[0059] (3) Lactobacillus plantarum cells were recovered by centrifugation (5000 g, 10 min, 4° C.), washed twice with magnesium salt buffer (100 mM NaCl, 8 mM MgSO4, 50 mM Tris-HCl, pH 8.0), and adjusted to OD = 2.0;

[0060] (4) D3G with a final concentration of 5 μg / mL and different concentrations of glucose, fructose, maltose, trehalose, cellobiose and sucrose were added for reaction; the DON content of D3G in the solution was detected by liquid chromatography-mass spectrometry (LC-MS / MS).

[0061] After research and screening, the inventors have identified preferred sugars, including: cellobiose, glucose, sucrose, maltose or trehalose. As is known in the art, there are many types of sugars, and the above-mentioned sugar substances are relatively effective substances for inhibiting conversion obtained by the inventors after screening.

[0062] The structural formula and molecular formula of the sugar are shown in Table 1.

[0063] Table 1

[0064]

[0065]

[0066] In the case where the inhibition effect of the carbohydrate substance is known, the present invention also includes the precursor of the carbohydrate substance. The "precursor" refers to the carbohydrate precursor that undergoes metabolism or chemical reaction and is converted into an active carbohydrate substance after being treated in an appropriate manner.

[0067] The present invention also includes isomers or solvates of the above-mentioned carbohydrate substances, as long as they have the same or substantially the same functions as the carbohydrate substances demonstrated in the embodiments of the present invention.

[0068] In the present invention, the added amount of the sugar substance is also optimized, thereby effectively improving the efficiency of inhibiting the conversion of D3G to DON.

[0069] As the most preferred embodiment of the present invention, the carbohydrate is cellobiose, which exhibits an unexpected conversion inhibition effect. Using the Lactobacillus model bacteria, the inventors compared the inhibitory effects of various carbohydrate substances. Cellobiose with a concentration of only 1g / L can achieve 100% inhibition of D3G conversion, which has a significantly more efficient inhibitory effect than other carbohydrates. Cellobiose, as a reducing sugar, has the advantages of high efficiency, safety and low cost, is suitable for large-scale application, and can be directly applied to crops or feed additions to prevent the risk of exposure of humans or animals to DON toxins.

[0070] It should be understood that in the method of the present invention, sugars are added exogenously at a specific time when toxic substances need to be reduced, with the purpose of inhibiting the conversion of D3G to DON, which is different from the carbon source in the cell culture medium or the flavoring substances (which may also include sugars) added during the processing of food / feed.

[0071] The method of the present invention can be applied to reduce the possibility of animals and humans ingesting toxic substances. Animals and humans have the phenomenon of releasing the prototype toxin DON after ingesting crops or products containing D3G. DON, as a fungal toxin, has immunotoxicity, organ toxicity, protein synthesis inhibition and teratogenicity. After being ingested by humans or animals, it will cause serious health problems. The sugar itself has the characteristics of high safety, so its processed products, natural substances, etc. will not pose a threat to the safety of humans or animals.

[0072] Lactobacillus family (such as Lactobacillus plantarum, Lactobacillus amyloliquefaciens, Lactobacillus crispatus, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus paracasei, Lactobacillus rhamnosus), Enterococcus family (such as Enterococcus casei, Enterococcus tenacious, Enterococcus faecium), Actinomycetaceae (such as Bifidobacterium adolescentis), Bifidobacterium family (such as Bifidobacterium, Bifidobacterium longum), Enterobacteriaceae (such as Citrobacter freundii, Enterobacter cloacae) are the main components of intestinal microorganisms. Among them, microorganisms such as Lactobacillus family and Actinomycetaceae not only exist in different ecological niches, but are also widely used in many food fermentations and commercially available probiotic products, and therefore often appear in human diets. According to research reports, these intestinal microorganisms have the ability to convert D3G into its prototype toxin DON to varying degrees, among which Lactobacillus family, especially Lactobacillus plantarum, has a higher D3G conversion efficiency, which undoubtedly increases the risk of DON exposure in humans and animals. Application of the method of the present invention can effectively avoid such strain-mediated conversion.

[0073] Compared with the prior art, the present invention has the following advantages and beneficial effects:

[0074] 1. It was discovered for the first time that carbohydrates, especially cellobiose, have the function of inhibiting the conversion of D3G by Lactobacillus plantarum, which has good application prospects.

[0075] 2. Carbohydrates, especially cellobiose, are efficient, safe and low-cost, and are suitable for large-scale applications.

[0076] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer.

[0077] Example 1, D3G transformation assay of Lactobacillus plantarum

[0078] Lactobacillus plantarum ATCC 14917 T A single colony was inoculated in MRS broth medium and grown for 24 hours at 37°C under dynamic incubation to activate the strain. The activated bacterial solution was transferred to 25 mL MRS broth medium at a ratio of 1:50 and cultured for 16 hours. The plant lactobacillus cells were then recovered by centrifugation (5000g, 10 minutes, 4°C), washed twice with magnesium salt buffer (100mMNaCl, 8mM MgSO4, 50mM Tris-HCl, pH 8.0), and adjusted to OD=4.0, and finally D3G was added to a final concentration of 5μg / mL for reaction. After 4 hours of reaction, the reaction was terminated by heating at 100°C for 10 minutes.

[0079] The sample after the above treatment was vortexed with a quarter volume of acetonitrile and then filtered through a 0.22 μm nylon filter. D3G and DON in the solution were detected by liquid chromatography-tandem triple quadrupole mass spectrometry LC-MS / MS. The liquid chromatography system was a Thermo Scientific Accela 1250UPLC system (Thermo Fisher Scientific, USA), and the chromatographic column was: Agilent Zorbax Extend-C18 column (100 mm×4.6 mm, 3.5 μg / ml). The mobile phase A was an aqueous solution containing 0.1% formic acid, and the mobile phase B was a methanol solution containing 0.1% formic acid, with a flow rate of 350 μL / min. The evaporator temperature was 300°C; the capillary temperature was 300°C; the sheath gas pressure was 10 psi; and the auxiliary gas pressure was 15 psi. The mass spectrometry analysis adopted the selected reaction monitoring mode (SRM).

[0080] The results of liquid chromatography detection are as follows Figure 1 The results showed that when D3G was used as the sole carbon source, Lactobacillus plantarum could convert D3G (low toxicity) into DON (high toxicity).

[0081] Example 2: Inhibitory effects of six sugars at different concentrations on the conversion of D3G by Lactobacillus plantarum

[0082] Lactobacillus plantarum ATCC 14917 TA single colony was inoculated in MRS broth medium and grown for 24 hours under dynamic incubation at 37°C to activate the strain. The activated bacterial solution was transferred to 25 mL MRS broth medium at a ratio of 1:50 and cultured for 16 hours. Subsequently, the plant lactobacillus cells were recovered by centrifugation (5000g, 10 minutes, 4°C), washed twice with magnesium salt buffer (100mMNaCl, 8mM MgSO4, 50mM Tris-HCl, pH 8.0), and adjusted to OD = 4.0 with magnesium salt buffer containing 1mg / L, 10mg / L, 100mg / L, 1g / L and 10g / L of glucose, fructose, maltose, sucrose, cellobiose and maltose, respectively, and finally D3G was added at a final concentration of 5μg / mL for 24 hours.

[0083] Subsequently, liquid chromatography tandem triple quadrupole mass spectrometry LC-MS / MS was used to detect D3G and DON in the solution.

[0084] The results showed that glucose, fructose, maltose, sucrose, cellobiose and maltose all showed significant inhibition of D3G conversion. However, compared with other sugars, cellobiose showed unexpected performance, which was able to inhibit D3G conversion more efficiently, and could inhibit D3G conversion by 100% at a concentration of 1g / L. Figure 2 .

[0085] according to Figure 2 Among them, the effect of cellobiose is particularly ideal. Although other sugars have certain effects, their conversion amount to DON is relatively limited.

[0086] It is worth emphasizing that DON is highly cytotoxic and will also affect cells at low concentrations (such as apoptosis, necrosis, endoplasmic reticulum stress, etc.). Therefore, the complete inhibition effect of cellobiose is a very ideal effect, which means that DON can be completely removed, and its application value will be much higher than that of several other sugar substances.

[0087] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims. At the same time, all the documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference separately.

Claims

1. A method for inhibiting the conversion of deoxynivalenol-3-glucoside into deoxynivalenol, characterized in that: include: Treating a microbial cell system containing deoxynivalenol-3-glucoside with sugars to inhibit the conversion of deoxynivalenol-3-glucoside into deoxynivalenol; the sugars include monosaccharides or disaccharides selected from: cellobiose, glucose, maltose, fructose or trehalose; the microorganism is Lactobacillus plantarum; The final concentration of cellobiose is 0.001-100 g / L; the final concentration of glucose is 0.001-100 g / L; the final concentration of fructose is 0.01-100 g / L; the final concentration of maltose is 0.8-100 g / L; and the final concentration of trehalose is 0.8-100 g / L.

2. The method according to claim 1, characterized in that The carbohydrate is cellobiose.

3. The method according to claim 1, characterized in that The microorganisms include living or inactivated microorganisms or processed products thereof.

4. The method according to claim 1, characterized in that When the microbial cell system containing deoxynivalenol-3-glucoside is treated with sugars, the final concentration of cellobiose is 0.5-50 g / L; the final concentration of glucose is 0.1-50 g / L; the final concentration of fructose is 0.1-20 g / L; the final concentration of maltose is 0.8-50 g / L; and the final concentration of trehalose is 0.8-50 g / L.

5. The method according to claim 4, characterized in that When the microbial cell system containing deoxynivalenol-3-glucoside is treated with sugars, the final concentration of cellobiose is 0.5-20 g / L; the final concentration of glucose is 0.1-20 g / L; the final concentration of fructose is 0.5-10 g / L; the final concentration of maltose is 0.8-10 g / L; and the final concentration of trehalose is 0.8-10 g / L.

6. The method according to claim 4, characterized in that When the microbial cell system containing deoxynivalenol-3-glucoside is treated with sugars, the final concentration of cellobiose is 1 to 10 g / L; the final concentration of glucose is 0.1 to 10 g / L; the final concentration of fructose is 1 to 10 g / L; the final concentration of maltose is 1 to 10 g / L; and the final concentration of trehalose is 1 to 10 g / L.

7. Use of carbohydrates for: inhibiting the conversion of deoxynivalenol-3-glucoside into deoxynivalenol in a microbial cell system containing deoxynivalenol-3-glucoside; or, preparing a composition for inhibiting the conversion of deoxynivalenol-3-glucoside into deoxynivalenol in a microbial cell system containing deoxynivalenol-3-glucoside; the carbohydrates include monosaccharides or disaccharides selected from: cellobiose, glucose, maltose, fructose or trehalose; the microorganism is Lactobacillus plantarum; The final concentration of cellobiose is 0.001-100 g / L; the final concentration of glucose is 0.001-100 g / L; the final concentration of fructose is 0.01-100 g / L; the final concentration of maltose is 0.8-100 g / L; and the final concentration of trehalose is 0.8-100 g / L.

8. The use according to claim 7, characterized in that The carbohydrate is cellobiose.

9. The use according to claim 7, characterized in that The final concentration of cellobiose is 0.5-50 g / L; the final concentration of glucose is 0.1-50 g / L; the final concentration of fructose is 0.1-20 g / L; the final concentration of maltose is 0.8-50 g / L; and the final concentration of trehalose is 0.8-50 g / L.

10. The use according to claim 9, characterized in that The final concentration of cellobiose is 0.5-20 g / L; the final concentration of glucose is 0.1-20 g / L; the final concentration of fructose is 0.5-10 g / L; the final concentration of maltose is 0.8-10 g / L; and the final concentration of trehalose is 0.8-10 g / L.

11. The use according to claim 10, characterized in that The final concentration of cellobiose is 1 to 10 g / L; the final concentration of glucose is 0.1 to 10 g / L; the final concentration of fructose is 1 to 10 g / L; the final concentration of maltose is 1 to 10 g / L; and the final concentration of trehalose is 1 to 10 g / L.

Images